f Current Trends and Challenges in Targeting Tumor Mitochondrial Glycolysis and Oxidative Phosphorylation Pathways for Cancer Therapy

References

1. NayakA. KapurA. BarroilhetL. PatankarM. Oxidative phosphorylation: A target for novel therapeutic strategies against ovarian cancer.Cancers (Basel)201810933710.3390/cancers1009033730231564
   [Google Scholar]
2. PollakM. Targeting oxidative phosphorylation: Why, when, and how.Cancer Cell201323326326410.1016/j.ccr.2013.02.01523518341
   [Google Scholar]
3. UllahA. ShehzadiS. UllahN. NawazT. IqbalH. AzizT. HypoxiaA. Hypoxia A typical target in human lung cancer therapy.Curr. Protein Pept. Sci.202325537638510.2174/011389203725282023111404523438031268
   [Google Scholar]
4. ZhaoY. HuX. LiuY. DongS. WenZ. HeW. ZhangS. HuangQ. ShiM. ROS signaling under metabolic stress: Cross-talk between AMPK and AKT pathway.Mol. Cancer20171617910.1186/s12943‑017‑0648‑128407774
   [Google Scholar]
5. BelisarioD.C. KopeckaJ. PasinoM. AkmanM. De SmaeleE. DonadelliM. RigantiC. Hypoxia dictates metabolic rewiring of tumors: Implications for chemoresistance.Cells2020912259810.3390/cells912259833291643
   [Google Scholar]
6. GhoshP. VidalC. DeyS. ZhangL. Mitochondria targeting as an effective strategy for cancer therapy.Int. J. Mol. Sci.2020219336310.3390/ijms2109336332397535
   [Google Scholar]
7. LuC.L. QinL. LiuH.C. CandasD. FanM. LiJ.J. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect.PLoS One2015103e012104610.1371/journal.pone.012104625807077
   [Google Scholar]
8. ShiratoriR. FuruichiK. YamaguchiM. MiyazakiN. AokiH. ChibanaH. ItoK. AokiS. Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner.Sci. Rep.2019911869910.1038/s41598‑019‑55296‑331822748
   [Google Scholar]
9. SaunierE. AntonioS. RegazzettiA. AuzeilN. LaprévoteO. ShayJ.W. CoumoulX. BaroukiR. BenelliC. HucL. BortoliS. Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells.Sci. Rep.201771694510.1038/s41598‑017‑07006‑028761044
   [Google Scholar]
10. ZhaoY. ChardL.S.D. ChengZ. WangY. SiL. Natural products targeting glycolysis in cancer.Front. Pharmacol.202213103650210.3389/fphar.2022.103650236386122
    [Google Scholar]
11. Mascaraque-ChecaM. Gallego-RenteroM. Nicolás-MoralaJ. Portillo-EsnaolaM. CuezvaJ.M. GonzálezS. GilaberteY. JuarranzÁ. Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy.Mol. Metab.20226010149610.1016/j.molmet.2022.10149635405370
    [Google Scholar]
12. Rubiño CarrilloE. Alcalá Domínguez-MartínA. Marchal BoulaizH. Phenformin as an anticancer agent: Challenges and prospects.Int. J. Mol. Sci.20192013331610.3390/ijms2013331631284513
    [Google Scholar]
13. BaccelliI. GareauY. LehnertzB. GingrasS. SpinellaJ.F. CorneauS. MayotteN. GirardS. FrechetteM. Blouin-ChagnonV. LeveilléK. BoivinI. MacRaeT. KroslJ. ThiollierC. LavalléeV.P. KanshinE. BertomeuT. Coulombe-HuntingtonJ. St-DenisC. BordeleauM.E. BoucherG. RouxP.P. LemieuxS. TyersM. ThibaultP. HébertJ. MarinierA. SauvageauG. Mubritinib targets the electron transport chain complex i and reveals the landscape of OXPHOS dependency in acute myeloid leukemia.Cancer Cell20193618499.e810.1016/j.ccell.2019.06.00331287994
    [Google Scholar]
14. BrambillaL. LahiriT. CammerM. LevyD.E. STAT3 inhibitor OPB-51602 is cytotoxic to tumor cells through inhibition of complex I and ROS induction.iScience2020231210182210.1016/j.isci.2020.10182233305182
    [Google Scholar]
15. AgnarelliA. NataliM. Garcia-GilM. PesiR. TozziM.G. IppolitoC. BernardiniN. VignaliR. BatistoniR. BianucciA.M. MarracciS. Cell-specific pattern of berberine pleiotropic effects on different human cell lines.Sci. Rep.2018811059910.1038/s41598‑018‑28952‑330006630
    [Google Scholar]
16. ShengX. WangM.M. ZhangG.D. SuY. FangH.B. YuZ.H. SuZ. Dual inhibition of oxidative phosphorylation and glycolysis to enhance cancer therapy.Bioorg. Chem.202414710732510.1016/j.bioorg.2024.10732538583247
    [Google Scholar]
17. CunhaA. SilvaP.M.A. SarmentoB. QueirósO. Targeting glucose metabolism in cancer cells as an approach to overcoming drug resistance.Pharmaceutics20231511261010.3390/pharmaceutics1511261038004589
    [Google Scholar]
18. SinghA.P. BiswasA. ShuklaA. MaitiP. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.Signal Transduct. Target. Ther.2019413310.1038/s41392‑019‑0068‑331637012
    [Google Scholar]
19. SasakiK. NishinaS. YamauchiA. FukudaK. HaraY. YamamuraM. EgashiraK. HinoK. Nanoparticle-mediated delivery of 2-Deoxy-D-Glucose induces antitumor immunity and cytotoxicity in liver tumors in mice.Cell. Mol. Gastroenterol. Hepatol.202111373976210.1016/j.jcmgh.2020.10.01033191170
    [Google Scholar]
20. HanX. SuR. HuangX. WangY. KuangX. ZhouS. LiuH. Triphenylphosphonium-modified mitochondria-targeted paclitaxel nanocrystals for overcoming multidrug resistance.Asian J Pharmaceut Sci201914556958010.1016/j.ajps.2018.06.00632104484
    [Google Scholar]
21. WangH. ZhangF. WenH. ShiW. HuangQ. HuangY. XieJ. LiP. ChenJ. QinL. ZhouY. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis.J. Nanobiotechnology2020181810.1186/s12951‑019‑0562‑331918714
    [Google Scholar]
22. PatraJ.K. DasG. FracetoL.F. CamposE.V.R. Rodriguez-TorresM.P. Acosta-TorresL.S. Diaz-TorresL.A. GrilloR. SwamyM.K. SharmaS. HabtemariamS. ShinH.S. Nano based drug delivery systems: Recent developments and future prospects.J. Nanobiotechnol20181617110.1186/s12951‑018‑0392‑830231877
    [Google Scholar]